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ABSTRACT
Australia’s model of antimicrobial stewardship
(AMS) has evolved significantly over recent
years, from a long-standing national approach
of antimicrobial prescribing guidelines and
antimicrobial prescribing restrictions to recent
advances including the first National
Antimicrobial Resistance Strategy and
incorporating mandatory AMS as part of
hospital accreditation standards. AMS
programs are most commonly found in the
hospital setting. Various models are used
throughout the country based on the local
context and resources available. Programs
implemented at Alfred Health and the Royal
Brisbane and Women’s Hospital represent two
successful models in tertiary referral settings
that accommodate a general ward setting as
well as specialized areas with a high infection
burden. Measurement of outcomes related to
AMS activities remains poorly standardized,
with process indicators such as antimicrobial
utilization forming a large proportion of
outcome measurement. Presently there is no
requirement for any AMS outcome
measurements to be reported externally. Point
prevalence surveys of appropriateness of
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prescribing and compliance with prescribing
guidelines are widely used at a national level.
Despite this, there is still a paucity of published
Australian data to support the effect of AMS on
patient clinical outcomes. Private hospitals, the
community, veterinary medicine and aged care
sectors represent an important area for future
AMS expansion within Australia. The AMS focus
has traditionally been on prescribing
restrictions (through the Commonwealth
funding agencies); however, recent work has
described other areas for improvement and
development in both settings. AMS in
Australia continues to evolve. The recent
development of an Australian strategic plan to
link antimicrobial utilization and resistance
surveillance with policy represents an
important step forward for the future of AMS
in Australia.
Keywords: Antimicrobial stewardship;
Australia; Infection prevention and control;
Resistance
INTRODUCTION
Australia’s model of antimicrobial stewardship
(AMS) has evolved over time and has adapted to
the organization and funding of the healthcare
system, the coordination and availability of
resources and prevalence of resistant
microorganisms. Australia has had a long
history of drug regulation and coordinated
policy that has formed a solid foundation for
AMS to be developed upon. Australia has
responded to the global need for AMS and
increased awareness, with significant advances
made in the last 5 years.
This article is based on previously conducted
studies and existing collections of
nonidentifiable data and therefore is exempted
from the need for ethical review according to
the Australian National Statement on Ethical
Conduct in Human Research (5.1.22, 2007).
THE AUSTRALIAN CONTEXT
In Australia’s healthcare system, there is a
division between primary care (including
outpatient pharmaceutical reimbursement),
which is funded by the Federal government,
and hospital care (including inpatient drug
costs) primarily operated by State and Territory
governments. In Australia, around 70% of
healthcare is provided by government-funded
public hospitals, with private hospitals
providing significant services, mostly in
obstetric and elective surgery [1].
Australia has had a long history of
standardized national treatment guidelines,
which allows for the implementation of
policies nationally across all levels of
healthcare, including primary care and
hospitals. These are developed by Therapeutic
Guidelines, an independent not-for-profit
organization that engages clinicians to review
and update the literature. National guidelines
have been an effective tool when combined
with broader regulatory policies [2]. The
National Prescribing Service (NPS), a
government-funded organization, has
implemented quality use of medicines
initiatives targeted at primary care
professionals and consumers [3].
Australia also has a strong system of hospital
accreditation standards analogous to the Joint
Commission in the USA. Of the ten National
Standards developed by the Australian
Commission on Safety and Quality in
Healthcare, one standard focuses on
preventing and controlling
healthcare-associated infections (standard 3)
and from 2013 onwards has included
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substandard 3.14, which is specific to AMS [4]. A
recently drafted set of Clinical Care Standards
has been developed providing
recommendations for the quality use of
antimicrobials [5].
The Australian healthcare system also has a
number of limitations that remain challenges
for implementation of AMS. Australia is yet to
widely implement an electronic medical record
despite government interest in this area [6].
Although electronic medical records are widely
used in primary care, a number of different
commercial systems are used, which is a
significant barrier to information exchange.
Electronic medical records and prescribing
systems are not yet commonplace in
Australian hospitals.
Surveillance for antimicrobial use and
antibiotic resistance is piecemeal and relies on
a patchwork of small systems. The Australian
Group on Antimicrobial Resistance (AGAR) has
performed centralized testing for selected
organisms, but this system is also voluntary
and based primarily on data from large
hospitals, which may bias reported results [7].
Public health surveillance systems cover
resistance in bacterial notifiable diseases
including pneumococci, tuberculosis, enteric
pathogens and Neisseria spp.
However, a number of recent developments
have provided a high-level policy framework to
coordinate the current patchwork of
surveillance and policy. After many years in
abeyance following the pioneering work of the
Joint Expert Technical Advisory Committee on
Antibiotic Resistance (JETACAR) [8] and Expert
Advisory Group on Antimicrobial Resistance
(EAGAR) [2], a national government
committee was established in 2012 to develop
a national strategy for antimicrobial resistance
following an Antimicrobial Resistance Summit
in 2011 [9, 10]. This group has developed the
first national strategy in June 2015 [11]
highlighting education, coordinated
surveillance and AMS across human and
animal health, infection prevention and
research as key to Australia’s response.
AMS IN HOSPITAL SETTINGS
The Development of Hospital AMS Models
in Australia
The Australian Commission on Safety and
Quality in Healthcare first published
guidelines for AMS in Australian Hospitals in
2011 [12]. These guidelines include the key
components essential for an AMS program in
Australia including antimicrobial formularies
and approval systems, prescriber education
and feedback, point of care interventions and
measurement of outcomes. These guidelines,
based on which many AMS programs are
developed, are being revised at the time of
writing.
Restriction policies have existed in many
Australian hospitals for many years, but formal
AMS programs, including governance structures
and multidisciplinary teams, are a more recent
development over the last 5–10 years. A survey
of hospitals in 2008 found that 80% of 78
surveyed Australian hospitals had a restricted
formulary for antimicrobial prescribing, but
only 25% had a multidisciplinary AMS team
[13]. By 2012, a Victorian survey found that
formulary restriction, auditing and feedback to
prescribers were implemented in a majority of
public metropolitan hospitals, but were not in
public regional hospitals or private hospitals
[14]. A Queensland survey also found that
formulary restrictions were the mainstay of
AMS programs, with auditing and feedback to
prescribers present in 76% of hospitals [15]. The
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incorporation of AMS into the National
Accreditation Standards for Australian
Hospitals in 2013 has mandated the need for
AMS and has been a driving factor for the
implementation and expansion of AMS in
Australia.
Models of AMS in Public Hospital Settings
The program implemented at Alfred Health in
Melbourne provides one example of a model of
AMS. At this health service, which includes
around 1000 hospital beds across three
campuses, an AMS Committee includes
representatives of pharmacy, infectious
diseases, microbiology as well as key prescriber
groups such as respiratory medicine, emergency
medicine, intensive care and surgery. This
committee oversees policies relating to
antimicrobial use and resistance, including the
development of local prescribing guidelines,
and monitoring and evaluation of the program.
Elements of the AMS program include
formulary restriction (requiring web-based
approval for most broad-spectrum antimicrobials
or specific approval from an infectious diseases
physician for selected agents), education of
prescribers and drug use evaluations and
reporting to unit heads on trends in
antimicrobial use. During the formative phase,
work was undertaken to achieve consensus on
approved indications for the use of antimicrobial
agents within the hospital, review of the formulary
restrictions and the availability of antimicrobial
agents within ward areas of the hospital and to
implement a web-based antimicrobial approval
system. An AMS team was formed and includes a
full time pharmacist as well as part time physicians
with expertise in infectious diseases, clinical
microbiology and epidemiology.
The AMS program has a different model of
engagement with areas with a moderate burden
of infection and antimicrobial use (including
general medicine, most surgical units) and
those with a high burden of infection and
antimicrobial use (such as intensive care,
haematology/bone marrow transplantation,
burns and cystic fibrosis/lung transplantation).
In the latter, the complex nature of patients and
need for timely access to broad-spectrum
antibiotics mitigates the effectiveness of
pre-prescription models of AMS, such as
formulary restriction.
In response to these limitations, AMS ward
rounds performing prospective auditing with
intervention and feedback for those units with a
moderate burden of infection form a key focus
of this program. This post-prescription model of
AMS has resulted in a reduction in the volume
of prescribing of several key classes of
antimicrobial agents [16].
Specialized Public Hospital Areas
with a High Infection Burden (e.g.,
Intensive Care Units)
The model of rapid audit and review is best
suited to patients that have a moderate burden
of infection and are of low to moderate
complexity. A different model of AMS is
required for highly complex patients with a
high burden of infection, such as in intensive
care, hematology/bone marrow transplant or
cystic fibrosis/lung transplantation. At some
Australian hospitals, infectious disease
physicians are ‘‘embedded’’ in these units,
performing conjoint ward rounds, liaising with
microbiology and clinical consultation, as well
as developing policies and clinical guidelines
covering both treatment and prevention of
infections in these groups.
An example of one model of AMS is that
found in the intensive care unit at The Royal
Brisbane and Women’s Hospital. This hospital
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has 30 intensive care beds and over 900 hospital
beds. The AMS activity is led by the intensive
care consultants with at least daily interaction
with nursing, pharmacy, infectious diseases and
microbiology teams. Although the intensive
care unit is a ‘‘closed’’ unit (intensive care
clinicians only have prescribing, admission
and discharge rights), it has strong
relationships with other relevant disciplines.
Twice weekly teaching management rounds
occur with infectious diseases, microbiology
and pharmacy team members reviewing all
patients with new or persisting microbiological
issues with attendance by infection control
practitioners. Patient consults by infectious
diseases physicians can occur up to daily as
needed.
Antimicrobial susceptibility patterns are
prepared annually by the Microbiology
Department. Optimized dosing is facilitated by
the Pharmacy Department in conjunction with
the Chemical Pathology Department, which
provides an extended therapeutic drug
monitoring service (aminoglycosides,
glycopeptides, beta-lactams, quinolones and
triazole antifungals). Dose adjustment is
supported by Bayesian dose optimization
methods in particularly complex patients.
Supporting the daily interactions of the
relevant team members is a strong program of
research, audit and guideline development led
by the intensive care team (medical, nursing
and pharmacy staff). Involvement of relevant
specialties is also an important component of
this work.
MONITORING AND EVALUATION
OF HOSPITAL AMS PROGRAMS
Assessment and measurement of the impact of
AMS clinical services in Australia remains
poorly standardized. Indicators used in
Australian hospitals include process indicators,
volume-based measures of antimicrobial use
and quality-based indicators of antimicrobial
use. Recently, clinical care standards for AMS
were released by the Australian Commission on
Safety and Quality in Healthcare, providing
useful guidance to hospitals to monitor and
evaluate AMS programs [5].
Process Indicators
In-house, site-specific data are often kept by
AMS teams, and currently there is no
requirement to report this externally. While
cost has been used to justify AMS programs, the
marked reduction in purchasing costs of
broad-spectrum antimicrobial agents within
Australia as generic formulations have become
available, suggests that this approach is unlikely
to be as successful and that other process
outcomes should be used for evaluation. Some
processes monitored at Alfred Health include
use of the electronic approval/alert system (see
Fig. 1a), the number of patients reviewed by an
AMS team per month and the number of
recommendations made by an AMS team per
month (see Fig. 1b). In addition, data are
reviewed on hospital-wide antimicrobial
utilization and changes in broad-spectrum
antimicrobial use [16].
Antimicrobial Use
Many hospitals contribute data on a voluntary
basis on antimicrobial utilization to the
National Antimicrobial Utilisation Surveillance
Program (NAUSP). These data are based on
pharmacy dispensing and distribution data
using the World Health Organization
(WHO)-defined daily dose method [17].
Although they provide useful data on
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prescribing trends over time, the nature of the
data source results in considerable
month-to-month variation, reflects the total
volume rather than the number of
prescriptions and does not provide data on the
appropriateness of use. In particular,
benchmarking between hospitals is difficult
because of variation in the patient case mix.
Point Prevalence Surveys
The National Antimicrobial Prescribing Survey
(NAPS) is an annual point prevalence survey
undertaken in November of each year to
coincide with Antimicrobial Awareness Week
[18]. This survey includes items to assess the
appropriateness of antimicrobial prescription
and compliance with guidelines (either
national or local). It has been conducted by an
increasing number of hospitals on a voluntary
basis since 2011 [18]. In 2013, it identified this
at 151 contributing hospitals (encompassing
approximately 12,800 individual antimicrobial
prescriptions). At these hospitals, 70.8% of
antimicrobial prescriptions were considered to
be appropriately prescribed, while 59.7% of
prescriptions were classed as compliant with



























































Fig. 1 Selected antimicrobial stewardship program
process indicators at Alfred Health. a Monthly number
of prescriber electronic approvals and pharmacist
notiﬁcations for use of restricted antimicrobials.
b Monthly number of patients reviewed by audit/feedback
rounds (left axis) and proportion of patients seen where a
recommendation was made to change antimicrobial
therapy (right axis)
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Clinical Outcomes
There has been a paucity of published AMS
studies focusing on clinical outcomes in the
Australian setting to date. The generalizability
of clinical studies from international
publications is limited because of differences
in infrastructure, resource availability and
antimicrobial resistance profiles. While the
link between antimicrobial use and resistance
is unambiguous mechanistically and on an
ecological scale, it has been more difficult to
demonstrate this link in hospital settings,
probably because of the many potential
confounders to this association. In Australia,
some studies have found a strong correlation
between decreasing antibiotic use and
decreasing gram-negative resistance following
a successful AMS program [20], but other studies
have failed to find associations between
broad-spectrum antimicrobial utilization
following the introduction of an AMS program
and observed rates of Clostridium difficile
infection [21].
Strengths and Limitations of Public
Hospital AMS Programs
Both our institutions considered the use of
pre-prescription and point of prescription
interventions. However, a program that relies
largely on antimicrobial restriction may
experience conflict with the need for timely
antimicrobial therapy, particularly in patients
with severe sepsis. Embedding authorization
with decision support tools has been
implemented, but in the absence of electronic
prescribing, it is not sustainable as it is not
embedded in prescriber workflow.
A key strength of programs that rely on
post-prescription audit and feedback includes
the recognition that the individual patient
clinical situation and subsequent
decision-making process are complex. Not all
patients can be encapsulated within clinical
guidelines, with significant patient-specific
factors requiring consideration. High visibility
and regular post-prescription antimicrobial
review enable insight into many aspects of
antimicrobial prescribing and use that may
not be recognized through other more passive
mechanisms of review, including prophylaxis
regimens and noninfectious use of
antimicrobial agents. Regular AMS rounds
provide regular teaching moments to junior
medical and pharmacy staff and enable
increased awareness and education about
infectious diseases and AMS principles.
In our experience, some limitations of the
current AMS programs include the inability at
present to link the AMS activities with direct
changes in both local and national antimicrobial
utilization, changes in antimicrobial resistance
rates and improvements in C. difficile rates. This
is exacerbated by the current piecemeal nature of
national antimicrobial surveillance. Capturing of
the exact antimicrobial utilization rates is also
limited by the absence of electronic prescribing
so that use can only be tracked to a ward rather
than the individual patient level. An ongoing
challenge for all AMS programs is maintaining
momentum and ensuring the sustainability of
the program. Finally, the labor-intensive nature
of this program is a major limitation to further
development of the program.
AMS IN OTHER SETTINGS
Private Hospitals
Although around 30% of all inpatient hospital
care in Australia occurs in the private hospital
sector [1], AMS in private hospitals has lagged
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behind that seen in public hospitals [14]. There
are significant cultural and organizational
differences for private hospitals when
compared to the Australian public sector,
which holds important implications for the
model of AMS that is feasible in this setting.
Principally, private hospitals often view their
role as facilitating and servicing medical
specialists’ practices. This is reflected in the
relatively autonomous practices of specialists,
the role of pharmacists in simply providing
medication rather than taking an active role in
medication management and the relative lack
of hospital-wide policies and coordinators of
AMS activities [22]. For example, infectious
diseases physicians are typically solely
responsible for their own patients, with no
additional hospital-wide role such as in
infection control or AMS. Likewise, clinical
microbiologists (employed by outsourced
pathology services) and pharmacists may be
limited to a supply function and do not have
jurisdiction to oversee AMS programs in private
hospitals [22].
There is, however, significant opportunity
for the private sector to tailor potential
solutions for successful AMS program
implementation. Establishing an antimicrobial
prescribing policy that makes specialists aware
of their responsibilities for judicious
antimicrobial use by ensuring the prescribing
policy forms part of their renewal for
accreditation to admit patients can send a
powerful message from hospital executive.
Pharmacists have been shown to be important
advocates of AMS [23], and there is significant
scope for them to lead post-prescription review
and periodic auditing if given the mandate to
do so. Due to their pivotal role in private
hospitals, nursing staff will clearly need to be
part of any AMS program in private hospitals
but further work is required to provide both the




Australia has a public subsidy for drugs through
the national Pharmaceutical Benefits
Scheme (PBS), and this has an important
influence on antimicrobial prescribing in
Australia. The effect of the PBS has best been
demonstrated for fluoroquinolones, where a
coordinated national policy has restricted
indications for use in national treatment
guidelines, the requirement for an ‘authority’
to be obtained to prescribe fluoroquinolones on
the PBS (medical practitioners need to call a
prescribing approval service to obtain approval
to prescribe) and the banning of
fluoroquinolone use in food-producing
animals [2]. This policy has resulted in a low
rate of fluoroquinolone use in Australia and a
relatively low rate of resistance to this valuable
class of antimicrobials [2].
The Drug Utilisation Subcommittee of the
Pharmaceutical Benefits Advisory Committee
recently released a review of the use of
antibiotics in primary care in Australia [24]. In
2013, they reported that 45% of the Australian
population were supplied at least one antibiotic
and that the overall utilization of antimicrobials in
Australia (22.8 Defined Daily Doses (DDDs)/1000
person days) was higher than the Organisation for
Economic Cooperation and Development average
(21.1 DDDs/1000 person days) [24]. The three
most commonly prescribed antimicrobial
agents were amoxycillin, cephalexin and
amoxycillin/clavulanate combinations [24].
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National Prescribing Service
The NPS is an independent,
government-funded organization founded in
1998 to improve the quality use of medicines
as a component of the National Medicines
Policy [25]. It aims to change attitudes and
behaviors that exist around the use of
medicines, and initiatives have included
antimicrobials in a current campaign that
commenced in 2012. They provide
educational programs to around half of
Australia’s general practitioners through
initiatives such as academic detailing and
clinical self-audits of prescribing practice. The
NPS is also providing broad consumer
education about antimicrobial resistance in a
current ‘‘Resistance Fighter’’ campaign [3].
Aged Care
In contrast to other countries, there are few
acute/subacute care long-term care facilities in
Australia, but around 8.5% of the elderly
[70 years live in residential aged care facilities
(RACFs), with various levels of nursing support
[26]. With increasing awareness of AMS in
recent years, the importance of RACFs as a
reservoir for multidrug-resistant (MDR)
organisms is becoming more apparent. A 2011
study by Stuart et al. identified low rates of
vancomycin-resistant enterococci (VRE) and C.
difficile colonization in a cohort of 119 patients
in Victoria, but a high prevalence of
extended-spectrum beta-lactamase
(ESBL)-producing Escherichia coli [27].
Similarly, another Melbourne study found that
36% of RACF residents were colonized with
methicillin-resistant Staphylococcus aureus
(MRSA), VRE or MDR gram-negative bacilli [28].
There is no ongoing surveillance of
antimicrobial use in Australian RACFs, but one
4-year Melbourne study has shown that the
majority of antimicrobial agents used were oral,
narrow-spectrum agents such as cephalexin and
trimethoprim [29]. However, it also highlighted
that a significant proportion of prescribing
appeared to occur in patients without obvious,
documented clinical findings suggestive of
infection and that none of the participating
RACFs had antimicrobial restriction policies in
place. Qualitative work has identified a number
of barriers and enablers to AMS in this setting
[30]. Workflow-related factors included the lack
of on-site medical care, pharmacy support,
nurse-driven infection management,
institutional policies and guidelines, and
external expertise and diagnostic facilities. A
subsequent survey found that stakeholders were
generally supportive of AMS interventions and
potential strategies included nursing-based
education, aged-care-specific antibiotic
guidelines and regular antibiotic surveillance
[31].
Veterinary Medicine
The role of AMS in veterinary medicine remains
in its infancy in Australia and lags behind that
of the human sector. There are currently no
nationally coordinated veterinary or
agricultural antimicrobial resistance
monitoring and surveillance programs in
Australia; however, a range of activities is
underway to address this issue, including the
Australian One Health Antimicrobial Resistance
Colloquium [32]. Historical sales data are
available between 2005 and 2010, with a
staggering 500–600 tons of active
antimicrobial agents being sold on average per
annum for the animal sector, with 98% of these
antimicrobials being used in food-producing
animals [33]. Approximately 40% of
antimicrobials were used for therapeutic effect
in animals, while 4–7% were used for growth
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promotion. There have been attempts to restrict
the veterinary use of antibiotics deemed to be
important therapeutic agents in human
medicine; significantly, fluoroquinolones are
not approved for use in Australian food
animals [2, 34].
CONCLUSIONS
AMS programs in Australia have evolved from
informal restriction policies to more
comprehensive programs with a formal
governance structure and multidisciplinary
teams. More broadly, an Australian strategic
plan has recently been developed to link
surveillance with policy across the various
domains of the healthcare system including
both antimicrobial use and antimicrobial
resistance, from primary care to aged care to
hospitals. The strategy also recognizes that
surveillance and AMS are required in animal
health. While some elements are similar,
different models of engagement are required
in different settings. Some examples of
successful strategies include regulation and
treatment guidelines in primary care,
nursing-led infection management in aged
care, and post-prescription audit and feedback
in hospitals. Further work is required to refine
and evaluate these and other models of AMS in
Australia.
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